Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis
- PMID:14752172
- DOI: 10.1093/rheumatology/keh105
Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis
Abstract
Licofelone, a competitive inhibitor of 5-lipoxygenase, cyclooxygenase (COX)-1 and COX-2, is currently in clinical development for the treatment of osteoarthritis (OA). Licofelone decreases the production of proinflammatory leukotrienes and prostaglandins-which are involved in the pathophysiology of OA and in gastrointestinal (GI) damage induced by NSAIDs-and has the potential to combine good analgesic and anti-inflammatory effects with excellent GI tolerability. Initial endoscopy data in healthy volunteers have demonstrated that licofelone is well tolerated and has a GI safety profile similar to placebo and significantly better than naproxen. These tolerability results were confirmed in patients with OA in two separate randomized studies. Furthermore, a long-term study (52 weeks) has shown that licofelone is at least as effective as naproxen in the treatment of OA. Licofelone also appears to be as effective as the selective COX-2 inhibitor celecoxib in the treatment of the signs and symptoms of OA. Licofelone has a GI safety profile similar to that of celecoxib, but may offer the advantage of fewer incidences or worsening of peripheral oedema. Preliminary data have also shown that licofelone coadministration with low-dose aspirin does not lead to increased GI toxicity. The emerging clinical data for licofelone indicate that it is an effective and well-tolerated therapy that could offer safety advantages over current treatment options, and that it could be suitable for the long-term treatment of a broad spectrum of patients with OA.
Similar articles
- Safety of anti-inflammatory treatment--new ways of thinking.Brune K.Brune K.Rheumatology (Oxford). 2004 Feb;43 Suppl 1:i16-20. doi: 10.1093/rheumatology/keh104.Rheumatology (Oxford). 2004.PMID:14752171Review.
- The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial.Bias P, Buchner A, Klesser B, Laufer S.Bias P, et al.Am J Gastroenterol. 2004 Apr;99(4):611-8. doi: 10.1111/j.1572-0241.2004.04133.x.Am J Gastroenterol. 2004.PMID:15089890Clinical Trial.
- Osteoarthritis therapy--are there still unmet needs?Laufer S.Laufer S.Rheumatology (Oxford). 2004 Feb;43 Suppl 1:i9-15. doi: 10.1093/rheumatology/keh103.Rheumatology (Oxford). 2004.PMID:14752170Review.
- Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?Geis GS.Geis GS.Scand J Rheumatol Suppl. 1999;109:31-7.Scand J Rheumatol Suppl. 1999.PMID:10422544Review.
- The metabolic effects of inhibitors of 5-lipoxygenase and of cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy.Celotti F, Durand T.Celotti F, et al.Prostaglandins Other Lipid Mediat. 2003 Jul;71(3-4):147-62. doi: 10.1016/s1098-8823(03)00039-x.Prostaglandins Other Lipid Mediat. 2003.PMID:14518558Review.
Cited by
- A COX/5-LOX Inhibitor Licofelone Revealed Anticonvulsant Properties Through iNOS Diminution in Mice.Payandemehr B, Khoshneviszadeh M, Varastehmoradi B, Gholizadeh R, Bahremand T, Attar H, Bahremand A, Dehpour AR.Payandemehr B, et al.Neurochem Res. 2015 Sep;40(9):1819-28. doi: 10.1007/s11064-015-1669-z. Epub 2015 Jul 28.Neurochem Res. 2015.PMID:26216049
- Towards safer anti-inflammatory therapy: synthesis of new thymol-pyrazole hybrids as dual COX-2/5-LOX inhibitors.El-Miligy MMM, Al-Kubeisi AK, Bekhit MG, El-Zemity SR, Nassra RA, Hazzaa AA.El-Miligy MMM, et al.J Enzyme Inhib Med Chem. 2023 Dec;38(1):294-308. doi: 10.1080/14756366.2022.2147164.J Enzyme Inhib Med Chem. 2023.PMID:36408833Free PMC article.
- Expression of 5-lipoxygenase in human colorectal cancer.Soumaoro LT, Iida S, Uetake H, Ishiguro M, Takagi Y, Higuchi T, Yasuno M, Enomoto M, Sugihara K.Soumaoro LT, et al.World J Gastroenterol. 2006 Oct 21;12(39):6355-60. doi: 10.3748/wjg.v12.i39.6355.World J Gastroenterol. 2006.PMID:17072961Free PMC article.
- Fighting age-related orthopedic diseases: focusing on ferroptosis.Ru Q, Li Y, Xie W, Ding Y, Chen L, Xu G, Wu Y, Wang F.Ru Q, et al.Bone Res. 2023 Mar 1;11(1):12. doi: 10.1038/s41413-023-00247-y.Bone Res. 2023.PMID:36854703Free PMC article.Review.
- Targeting leukotriene biosynthesis to prevent atherosclerotic cardiovascular disease.Wang X, Baskaran L, Chan M, Boisvert W, Hausenloy DJ.Wang X, et al.Cond Med. 2023 Apr;6(2):33-41.Cond Med. 2023.PMID:38800614Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials